Somatostatin modulators and uses thereof

1. A compound that has the structure of Formula (I), or a pharmaceutically acceptable salt, solvate, diastereomeric mixture, or individual enantiomers thereof:

wherein:

R 1 and R 2 are taken together with the carbon atom to which they are attached to form —C(═O)—;

or R 1 and R 2 are each independently selected from the group consisting of hydrogen, and unsubstituted or substituted C 1 -C 6 alkyl;

R A is a cyclic ring that is an unsubstituted or substituted monocyclic carbocycle, unsubstituted or substituted bicyclic carbocycle, unsubstituted or substituted monocyclic heterocycle, or unsubstituted or substituted bicyclic heterocycle, wherein if R A is substituted then R A is substituted with 1-2 R 10 and 0-2 R 11 ;

R B is a cyclic ring that is an unsubstituted or substituted monocyclic carbocycle, unsubstituted or substituted bicylcic carbocycle, unsubstituted or substituted monocyclic heterocycle, unsubstituted or substituted bicyclic heterocycle, wherein if R B is substituted then R B is substituted with 1-2 R 12 and 0-2 R 13 ;

A 1 , A 2 , and A 3 are independently CR C or N;

each R C is independently hydrogen, F, Cl, Br, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, tert-butyl, monofluoromethyl, difluoromethyl, trifluoromethyl, methoxy, ethoxy, trifluoromethoxy, —CN, —OH, —CO 2 R 14 , —C(═O)NR 14 R 15 , —C(═NOR 14 )R 15 , —SR 14 , —S(═O)(C 1 -C 4 alkyl), —SO 2 (C 1 -C 4 alkyl) or —SO 2 NR 14 R 15 ;

R 3 and R 4 are independently hydrogen, unsubstituted or substituted C 1 -C 6 alkyl, unsubstituted or substituted C 1 -C 6 fluoroalkyl, or unsubstituted or substituted C 3 -C 6 cycloalkyl, wherein any substituted group of R 3 and R 4 is substituted with 1-4 R 16 ;

or R 3 and R 4 are taken together with the nitrogen atom to which they are attached to form an unsubstituted or substituted monocyclic or bicyclic heterocyclic ring, wherein if the heterocyclic ring is substituted then the heterocyclic ring is substituted with 1-4 R 16 ;

R 5 , R 6 , R 7 , and R 8 are each independently selected from the group consisting of hydrogen, unsubstituted or substituted C 1 -C 6 alkyl, unsubstituted or substituted C 1 -C 6 fluoroalkyl, unsubstituted or substituted monocyclic carbocycle, and unsubstituted or substituted monocyclic heterocycle, wherein any substituted group of R 5 , R 6 , R 7 , and R 8 is substituted with 1-4 R 16 ;

R 9 is hydrogen, unsubstituted or substituted C 1 -C 6 alkyl, unsubstituted or substituted benzyl, wherein if R 9 is substituted then R 9 is substituted with 1-4 R 16 ;

or R 4 and any one of R 5 , R 7 , or R 9 are taken together with the intervening atoms to which they are attached to form an unsubstituted or substituted monocyclic 4- to 7-membered heterocyclic ring or an unsubstituted or substituted bicyclic 9- to 12-membered heterocyclic ring, wherein if the heterocyclic ring is substituted then the heterocyclic ring is substituted with 1-4 R 16 ;

or R 5 and any one of R 6 , R 7 or R 9 are taken together with the intervening atoms to which they are attached to form an unsubstituted or substituted monocyclic 4- to 7-membered ring or a bicyclic 9- to 12-membered ring, wherein if the heterocyclic ring is substituted then the heterocyclic ring is substituted with 1-4 R 16 ;

or R 7 and R 9 are taken together with the intervening atoms to which they are attached to form an unsubstituted or substituted monocyclic 4- to 7-membered heterocyclic ring or an unsubstituted or substituted bicyclic 9- to 12-membered heterocyclic ring, wherein if the heterocyclic ring is substituted then the heterocyclic ring is substituted with 1-4 R 16 ;

each R 10 , R 11 , R 12 and R 13 is independently hydrogen, halogen, unsubstituted or substituted C 1 -C 4 alkyl, unsubstituted or substituted C 1 -C 4 alkoxy, unsubstituted or substituted C 1 -C 4 fluoroalkyl, unsubstituted or substituted C 1 -C 4 fluoroalkoxy, unsubstituted or substituted monocyclic carbocycle, unsubstituted or substituted monocyclic heterocycle, —CN, —OH, —CO 2 R 14 , —CH 2 CO 2 R 14 , —C(═O)NR 14 R 15 , —CH 2 C(═O)NR 14 R 15 , —NR 14 R 15 , —CH 2 NR 14 R 15 , —NR 14 C(═O)R 15 , —CH 2 NR 14 C(═O)R 15 , —SR 14 , —S(═O)R 15 , —SO 2 R 15 , or —SO 2 NR 14 R 15 , wherein if any group of R 10 , R 11 , R 12 and R 13 is substituted then the substituted group of R 10 , R 11 , R 12 and R 13 is substituted with 1-4 R 16 ;

each R 16 is independently halogen, C 1 -C 6 alkyl, heterocycle, —CN, —OR 14 , —CO 2 R 14 , —C(═O)NR 14 R 15 , —NR 14 R 15 , —NR 14 C(═O)R 15 , —SR 14 , —S(═O)R 15 , —SO 2 R 15 , or —SO 2 NR 14 R 15 ;

each R 14 is independently selected from H, unsubstituted or substituted C 1 -C 6 alkyl, unsubstituted or substituted C 1 -C 6 heteroalkyl, unsubstituted or substituted C 3 -C 10 cycloalkyl, substituted or unsubstituted C 2 -C 10 heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;

each R 15 is independently selected from H, unsubstituted or substituted C 1 -C 6 alkyl, unsubstituted or substituted C 1 -C 6 heteroalkyl, unsubstituted or substituted C 3 -C 10 cycloalkyl, substituted or unsubstituted C 2 -C 10 heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; or R 14 and R 15 are taken together with the N atom to which they are attached to a substituted or unsubstituted N-containing heterocycle; and

m is 1, 2, 3, or 4.

2. The compound of claim 1 , or a pharmaceutically acceptable salt, solvate, diastereomeric mixture, or individual enantiomers thereof, wherein:

R 1 and R 2 are taken together with the carbon atom to which they are attached to form —C(═O)—; and

m is 1 or 2.

3. The compound of claim 1 , or a pharmaceutically acceptable salt, solvate, diastereomeric mixture, or individual enantiomers thereof, wherein:

A 1 , A 2 , and A 3 are CR C ;

or A 1 is N; and A 2 and A 3 are CR C ;

or A 1 and A 3 are CR C ; and A 2 is N;

or A 1 and A 2 are CR C ; and A 3 is N;

or A 1 and A 2 are N; and A 3 is CR C ;

or A 1 and A 3 are N; and A 2 is CR C .

4. The compound of claim 1 , or a pharmaceutically acceptable salt, solvate, diastereomeric mixture, or individual enantiomers thereof, wherein:

R 3 and R 4 are each independently selected from the group consisting of hydrogen, unsubstituted or substituted C 1 -C 6 alkyl, and unsubstituted or substituted C 1 -C 6 fluoroalkyl, wherein any substituted group of R 3 and R 4 is substituted with 1-4 R 16 .

5. The compound of claim 1 , wherein the compound of Formula (I) has the structure of Formula (Ia), Formula (Ib), Formula (Ic), Formula (Id), Formula (Ie), or Formula (If), or a pharmaceutically acceptable salt, solvate, diastereomeric mixture, or individual enantiomers thereof:

6. The compound of claim 1 , or a pharmaceutically acceptable salt, solvate, diastereomeric mixture, or individual enantiomers thereof, wherein:

R A is an unsubstituted or substituted phenyl, wherein if R A is substituted then R A is substituted with 1-2 R 10 and 0-2 R 11 ; and

R B is an unsubstituted or substituted phenyl, wherein if R B is substituted then R B is substituted with 1-2 R 12 and 0-2 R 13 .

7. The compound of claim 1 , or a pharmaceutically acceptable salt, solvate, diastereomeric mixture, or individual enantiomers thereof, wherein:

R A is

R B is

n is 0, 1, or 2; and

t is 0, 1, or 2.

8. The compound of claim 1 , or a pharmaceutically acceptable salt, solvate, diastereomeric mixture, or individual enantiomers thereof, wherein:

R A is

and

R B is

9. The compound of claim 1 , or a pharmaceutically acceptable salt, solvate, diastereomeric mixture, or individual enantiomers thereof, wherein:

each R 10 is independently hydrogen, halogen, unsubstituted or substituted C 1 -C 4 alkyl, unsubstituted or substituted C 1 -C 4 alkoxy, unsubstituted or substituted C 1 -C 4 fluoroalkyl, unsubstituted or substituted C 1 -C 4 fluoroalkoxy, unsubstituted or substituted monocyclic carbocycle, unsubstituted or substituted monocyclic heterocycle, —CN, —OH, —CO 2 R 14 , —CH 2 CO 2 R 14 , —C(═O)NR 14 R 15 , —CH 2 C(═O)NR 14 R 15 , —NR 14 R 15 , —CH 2 NR 14 R 15 , —NR 14 C(═O)R 15 , —CH 2 NR 14 C(═O)R 15 , —SR 14 , —S(═O)R 15 , —SO 2 R 15 , or —SO 2 NR 14 R 15 , wherein if R 10 is substituted then R 10 is substituted with 1-4 R 16 ;

each R 11 is independently hydrogen, halogen, unsubstituted or substituted C 1 -C 4 alkyl, unsubstituted or substituted C 1 -C 4 alkoxy, unsubstituted or substituted C 1 -C 4 fluoroalkyl, unsubstituted or substituted C 1 -C 4 fluoroalkoxy, —CN, or —OH, wherein if R 11 is substituted then R 11 is substituted with 1-4 R 16 ;

each R 12 is independently hydrogen, halogen, unsubstituted or substituted C 1 -C 4 alkyl, unsubstituted or substituted C 1 -C 4 alkoxy, unsubstituted or substituted C 1 -C 4 fluoroalkyl, unsubstituted or substituted C 1 -C 4 fluoroalkoxy, unsubstituted or substituted monocyclic carbocycle, unsubstituted or substituted monocyclic heterocycle, —CN, —OH, —CO 2 R 14 , —CH 2 CO 2 R 14 , —C(═O)NR 14 R 15 , —CH 2 C(═O)NR 14 R 15 , —NR 14 R 15 , —CH 2 NR 14 R 15 , —NR 14 C(═O)R 15 , —CH 2 NR 14 C(═O)R 15 , —SR 14 , —S(═O)R 15 , —SO 2 R 15 , or —SO 2 NR 14 R 15 , wherein if R 12 is substituted then R 12 is substituted with R 16 ; and

each R 13 is independently hydrogen, halogen, unsubstituted or substituted C 1 -C 4 alkyl, unsubstituted or substituted C 1 -C 4 alkoxy, unsubstituted or substituted C 1 -C 4 fluoroalkyl, unsubstituted or substituted C 1 -C 4 fluoroalkoxy, unsubstituted or substituted monocyclic carbocycle, unsubstituted or substituted monocyclic heterocycle, —CN, —OH, wherein if R 13 is substituted then R 13 is substituted with R 16 .

10. The compound of claim 1 , or a pharmaceutically acceptable salt, solvate, diastereomeric mixture, or individual enantiomers thereof, wherein:

each R 10 is independently hydrogen, halogen, unsubstituted or substituted C 1 -C 4 alkyl, unsubstituted or substituted C 1 -C 4 alkoxy, C 1 -C 4 fluoroalkyl, C 1 -C 4 fluoroalkoxy, unsubstituted or substituted phenyl, unsubstituted or substituted monocyclic heterocycle, —CN, —OH, —CO 2 R 14 , —CH 2 CO 2 R 14 , —C(═O)NR 14 R 15 , —CH 2 C(═O)NR 14 R 15 , —NR 14 R 15 , —CH 2 NR 14 R 15 , —NR 14 C(═O)R 15 , or —CH 2 NR 14 C(═O)R 15 , wherein if R 10 is substituted then R 10 is substituted with 1-4 R 16 ; and

each R 11 is independently hydrogen, halogen, unsubstituted or substituted C 1 -C 4 alkyl, C 1 -C 4 fluoroalkyl, C 1 -C 4 alkoxy, C 1 -C 4 fluoroalkoxy, or —CN, wherein if R 11 is substituted then R 11 is substituted with —OR 14 or —NR 14 R 15 .

11. The compound of claim 1 , or a pharmaceutically acceptable salt, solvate, diastereomeric mixture, or individual enantiomers thereof, wherein:

R 4 is hydrogen, or unsubstituted or substituted C 1 -C 6 alkyl, wherein if R 4 is substituted then it is substituted with 1-4 R 16 ;

R 5 is hydrogen, or unsubstituted or substituted C 1 -C 6 alkyl, wherein if R 5 is substituted then it is substituted with 1-4 R 16 ;

R 7 is hydrogen;

or R 4 and R 5 are taken together with the nitrogen atom to which they are attached to form a monocyclic 4- to 7-membered heterocyclic ring, wherein if the heterocyclic ring is substituted then the heterocyclic ring is substituted with 1-4 R 16 ;

or R 4 and R 7 are taken together with the nitrogen atom to which they are attached to form a monocyclic 4- to 7-membered heterocyclic ring, wherein if the heterocyclic ring is substituted then the heterocyclic ring is substituted with 1-4 R 16 ; and

R 9 is hydrogen, unsubstituted or substituted C 1 -C 6 alkyl, or unsubstituted or substituted benzyl, wherein if R 9 is substituted then R 9 is substituted with 1-4 R 16 .

12. The compound of claim 1 , or a pharmaceutically acceptable salt, solvate, diastereomeric mixture, or individual enantiomers thereof, wherein:

R 4 is hydrogen, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, or tert-butyl;

R 5 is hydrogen, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, or tert-butyl;

R 7 is hydrogen;

or R 4 and R 5 are taken together with the nitrogen atom to which they are attached to form an unsubstituted or substituted monocyclic 4- to 7-membered heterocyclic ring selected from unsubstituted or substituted azetidinyl, unsubstituted or substituted pyrrolidinyl, unsubstituted or substituted pyrrolidinonyl, unsubstituted or substituted piperidinyl, unsubstituted or substituted morpholinyl, unsubstituted or substituted thiomorpholinyl, unsubstituted or substituted piperazinyl, or unsubstituted or substituted azepanyl, wherein if the heterocyclic ring is substituted then the heterocyclic ring is substituted with 1-4 R 16 ;

or R 4 and R 7 are taken together with the nitrogen atom to which they are attached to form an unsubstituted or substituted monocyclic 4- to 7-membered heterocyclic ring selected from unsubstituted or substituted azetidinyl, unsubstituted or substituted pyrrolidinyl, unsubstituted or substituted pyrrolidinonyl, unsubstituted or substituted piperidinyl, unsubstituted or substituted morpholinyl, unsubstituted or substituted thiomorpholinyl, unsubstituted or substituted piperazinyl, or unsubstituted or substituted azepanyl, wherein if the heterocyclic ring is substituted then the heterocyclic ring is substituted with 1-4 R 16 ; and

R 9 is methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, tert-butyl, or benzyl.

13. The compound of claim 5 , or a pharmaceutically acceptable salt, solvate, diastereomeric mixture, or individual enantiomers thereof,

wherein:

14. The compound of claim 13 , or a pharmaceutically acceptable salt, solvate, diastereomeric mixture, or individual enantiomers thereof,

wherein:

R 4 is hydrogen, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, or tert-butyl;

R 5 is hydrogen, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, or tert-butyl;

R 7 is hydrogen; and

R 9 is methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, tert-butyl, or benzyl.

15. The compound of claim 5 , or a pharmaceutically acceptable salt, solvate, diastereomeric mixture, or individual enantiomers thereof,

wherein:

p is 1, 2, or 3;

q is 0, 1, or 2; and

R 9 is methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, tert-butyl, or benzyl.

16. The compound of claim 5 , or a pharmaceutically acceptable salt, solvate, diastereomeric mixture, or individual enantiomers thereof, wherein:

p is 1, 2, or 3;

q is 0, 1, or 2; and

R 9 is methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, tert-butyl, or benzyl.

17. A compound that is:

1-1: 3-(3-chloro-5-methylphenyl)-6-(3-hydroxyphenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

1-2: N-[(2S)-2-aminopropyl]-3-(3-chloro-5-methylphenyl)-6-(3-hydroxyphenyl)-N -methylquinoline-4-carboxamide;

1-3: N-[(2S)-2-aminobutyl]-3-(3-chloro-5-methylphenyl)-6-(3-hydroxyphenyl)-N -methylquinoline-4-carboxamide;

1-4: 3-(3-fluoro-5-methylphenyl)-6-(3-hydroxyphenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

1-5: 3-(3-chloro-5-methylphenyl)-6-(3-hydroxyphenyl)-N-methyl-N-[(2R)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

1-6: 3-(3-fluoro-5-methoxyphenyl)-6-(3-hydroxyphenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

1-7: N-[(2S)-azetidin-2-ylmethyl]-3-(3-fluoro-5-methylphenyl)-6-(3-hydroxyphenyl)-N -methylquinoline-4-carboxamide;

1-8: N-[(2S)-2-aminobutyl]-6-(3-carbamoyl-5-hydroxyphenyl)-3-(3-chloro-5-methylphenyl)-N -methylquinoline-4-carboxamide;

1-9: N-[(2S)-2-aminobutyl]-6-(3-cyano-5-methoxyphenyl)-3-(3-fluoro-5-methylphenyl)-N -methylquinoline-4-carboxamide;

1-10: N-[(2S)-2-aminobutyl]-6-(3-cyano-5-hydroxyphenyl)-3-(3-fluoro-5-methylphenyl)-N -methylquinoline-4-carboxamide;

1-11: N-[(2S)-2-aminobutyl]-3-(3-fluoro-5-methylphenyl)-6-(5-hydroxy-2-methylphenyl)-N -methylquinoline-4-carboxamide;

1-12: N-[(2S)-2-aminobutyl]-6-(3-cyano-2-methylphenyl)-3-(3-fluoro-5-methylphenyl)-N -methylquinoline-4-carboxamide;

1-13: N-[(2S)-2-aminobutyl]-6-(3-fluoro-2-methylphenyl)-3-(3-fluoro-5-methylphenyl)-N -methylquinoline-4-carboxamide;

1-14: N-[(2S)-2-aminobutyl]-6-(5-cyano-2-methylphenyl)-3-(3-fluoro-5-methylphenyl)-N -methylquinoline-4-carboxamide;

1-15: N-[(2S)-2-aminobutyl]-6-(3-cyano-5-fluorophenyl)-3-(3-fluoro-5-methylphenyl)-N -methylquinoline-4-carboxamide;

1-16: 6-(3-cyanophenyl)-3-(3-fluoro-5-methylphenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

1-17: N-[(2S)-2-aminobutyl]-6-(3-fluoro-5-methoxyphenyl)-3-(3-fluoro-5-methylphenyl)-N -methylquinoline-4-carboxamide;

1-18: 3-(3-fluorophenyl)-6-(3-hydroxyphenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

1-19: N-[(2S)-2-aminopropyl]-6-(3-cyano-5-methoxyphenyl)-3-(3-fluoro-5-methylphenyl)-N -methylquinoline-4-carboxamide;

1-20: N-[(2S)-2-aminopropyl]-6-(3-cyano-5-fluorophenyl)-3-(3-fluoro-5-methylphenyl)-N -methylquinoline-4-carboxamide;

1-21: 6-(3-cyano-5-methoxyphenyl)-3-(3-fluoro-5-methylphenyl)-N-methyl-N-[(2S) -pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

1-22: 6-(3-cyano-5-fluorophenyl)-3-(3,5-difluorophenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

1-23: 3-(3,5-difluorophenyl)-6-(2-fluoro-3-hydroxyphenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

1-24: 6-(3-cyano-5-fluorophenyl)-3-(3-fluoro-5-methylphenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

1-25: 6-(3 -cyano-2-fluorophenyl)-3-(3,5-difluorophenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

1-26: 6-(3-carbamoyl-5-fluorophenyl)-3-(3,5-difluorophenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

1-27: 6-(5-cyano-2-methoxyphenyl)-3-(3,5-difluorophenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

1-28: 6-(5-cyano-2-fluorophenyl)-3-(3,5-difluorophenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

1-29: 3 -(3-fluoro-5-methylphenyl)-6-(3-hydroxyphenyl)-N-methyl-N-(morpholin-3-ylmethyl)quinoline-4-carboxamide;

1-30: 6-(3-cyano-5-methoxyphenyl)-3-(3,5-difluorophenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

1-31: 6-(2-chloro-3-hydroxyphenyl)-3-(3,5-difluorophenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

1-32: N-[(2S)-2-aminobutyl]-6-(3-cyano-5-methoxyphenyl)-3-(3,5-difluorophenyl)-N -methylquinoline-4-carboxamide;

1-33: 6-(3-carbamoyl-5-fluorophenyl)-3-(3-fluoro-5-methylphenyl)-N-methyl-N-[(2S) -pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

1-34: 6-(3-cyano-5-fluorophenyl)-3-(3-fluoro-5-hydroxyphenyl)-N-methyl-N-[(2S)-pyrrolidin -2-ylmethyl]quinoline-4-carboxamide;

1-35: 6-(3-cyano-5-fluorophenyl)-3-[3-fluoro-5-(2-hydroxyethyl)phenyl]-N-methyl-N-[(2S) -pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

1-36: 3 -fluoro-5-[3-(3-fluoro-5-methylphenyl)-4-{methyl[(2S)-pyrrolidin-2-ylmethyl]carbamoyl}quinolin-6-yl]benzoic acid;

1-37: 4-{3-[6-(3-cyano-5-fluorophenyl)-4-{methyl[(2S)-pyrrolidin-2-ylmethyl]carbamoyl}quinolin-3-yl]-5-fluorophenoxy}butanoic acid;

1-38: N-[(2 S)-2-aminobutyl]-6-(3-cyano-5-hydroxyphenyl)-3-(3,5-difluorophenyl)-N -methylquinoline-4-carboxamide;

1-39: 6-(3-cyano-5-fluorophenyl)-3-[3-fluoro-5-(2-hydroxyethoxy)phenyl]-N-methyl-N-[(2S) -pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

1-40: 6-[3-cyano-5-(trifluoromethyl)phenyl]-3-(3-fluoro-5-methylphenyl)-N-methyl-N-[(2S) -pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

1-41: 6-(2-chloro-3-hydroxyphenyl)-3-(3-fluoro-5-methylphenyl)-N-methyl-N-[(2S) -pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

1-42: 6-(3-cyano-5-fluorophenyl)-3-[3-fluoro-5-(2-methoxyethoxy)phenyl]-N-methyl-N-[(2S) -pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

1-43: 3 -(3-fluoro-5 -methylphenyl)-6- [3-hydroxy-2-(methoxymethyl)phenyl]-N-methyl-N -[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide

1-44: 3-[3-(3-fluoro-5-methylphenyl)-4-{methyl[(2S)-pyrrolidin-2-ylmethyl]carbamoyl}quinolin-6-yl]benzoic acid;

1-45: 6-(3-cyano-2-methylphenyl)-3-[3-fluoro-5-(2-hydroxyethyl)phenyl]-N-methyl-N-[(2S) -pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

1-46: 4-[3-(3-fluoro-5-methylphenyl)-4-{methyl[(2S)-pyrrolidin-2-ylmethyl]carbamoyl}quinolin-6-yl]benzoic acid;

1-47: 2-[3-(3-fluoro-5-methylphenyl)-4-{methyl[(2S)-pyrrolidin-2-ylmethyl]carbamoyl}quinolin-6-yl]benzoic acid;

1-48: 2-{3-[3-(3-fluoro-5-methylphenyl)-4-{methyl[(2S)-pyrrolidin-2-ylmethyl]carbamoyl}quinolin-6-yl]phenyl}acetic acid;

1-49: methyl 2-{3-[3-(3-fluoro-5-methylphenyl)-4-{methyl[(2S)-pyrrolidin-2-ylmethyl]carbamoyl}quinolin-6-yl]phenyl}acetate;

1-50: 3-{3-[3-(3-fluoro-5-methylphenyl)-4-{methyl[(2 S)-pyrrolidin-2-ylmethyl]carbamoyl}quinolin-6-yl]phenyl}propanoic acid;

1-51: 6-(3-cyano-2-methylphenyl)-3-(3,5-difluorophenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

1-52: 6-(5-cyano-2-methylphenyl)-3-(3,5-difluorophenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

1-53: 6-(3 -carbamoyl-2-fluorophenyl)-3-(3-fluoro-5-methylphenyl)-N-methyl-N-[(2S) -pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

1-54: 6-(3-carbamoyl-4-fluorophenyl)-3-(3-fluoro-5-methylphenyl)-N-methyl-N-[(2S) -pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

1-55: N-[(2S)-2-aminobutyl]-6-(3-cyano-5-fluorophenyl)-3-(3,5-difluorophenyl)-N -methylquinoline-4-carboxamide;

1-56: 6-(3-cyano-5-fluorophenyl)-3-(2,5-difluorophenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

1-57: 3-(2-chloro-5-methylphenyl)-6-(3-cyano-5-fluorophenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

1-58: 6-(3-cyano-5-fluorophenyl)-3-(5-fluoro-2-methylphenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

1-59: 2-{3-fluoro-5-[3-(3-fluoro-5-methylphenyl)-4-{methyl[(2S)-pyrrolidin-2-ylmethyl]carbamoyl}quinolin-6-yl]phenyl}acetic acid;

1-60: 3-(3-fluoro-5-methylphenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]-6-(3-sulfamoylphenyl)quinoline-4-carboxamide;

1-61: 6-(3,5-difluorophenyl)-3-(3-fluoro-5-methylphenyl)-N-methyl-N-[(3S)-pyrrolidin-3-yl]quinoline-4-carboxamide;

1-62: 6-(3,5-difluorophenyl)-3-(3-fluoro-5-methylphenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

1-63: 6-(6-carbamoylpyrazin-2-yl)-3-(3-fluoro-5-methylphenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

1-64: 6-(2-chloro-5-methoxyphenyl)-3-(3-fluoro-5-methylphenyl)-N-methyl-N-[(2S)-pyrrolidin -2-ylmethyl]quinoline-4-carboxamide;

1-65: 2-{3-chloro-5-[6-(3-cyano-5-fluorophenyl)-4-{methyl[(2S)-pyrrolidin-2-ylmethyl]carbamoyl}quinolin-3-yl]phenoxy}acetic acid;

1-66: 3-(3-fluoro-5-methylphenyl)-6-(3-fluoro-5-sulfamoylphenyl)-N-methyl-N-[(2S) -pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

1-67: 6-(3-cyano-5-fluorophenyl)-3-(2,3-difluorophenyl)-N-methyl-N- [(2 S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

1-68: N-[(2S)-2-amino-3-methylbutyl]-6-(3,5-difluorophenyl)-3-(3-fluoro-5-methylphenyl)-N -methylquinoline-4-carboxamide;

1-69: 6-(3-cyano-5-fluorophenyl)-3-[3-fluoro-5-(2-hydroxypropan-2-yl)phenyl]-N-methyl-N -[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

1-70: N-[(2S)-2-aminobutyl]-6-[3-fluoro-5-(trifluoromethyl)phenyl]-3-(3-fluoro-5-methylphenyl)-N-methylquinoline-4-carboxamide;

1-71: 6-(3-cyano-5-fluorophenyl)-3-[3-fluoro-5-(prop-1-en-2-yl)phenyl]-N-methyl-N-[(2S) -pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

1-72: 6-(3-carbamoyl-4-hydroxyphenyl)-3-(3-fluoro-5-methylphenyl)-N-methyl-N-[(2S) -pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

1-73: 3-[3-(dimethylcarbamoyl)phenyl]-6-(3-hydroxyphenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

1-74: 6- [3-(carbamoylmethyl)-5-fluorophenyl]-3-(3-fluoro-5-methylphenyl)-N-methyl-N -[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

1-75: N- [(2 S)-2-aminopropyl]-6-(3-carbamoyl-5-methoxyphenyl)-3-(3-fluoro-5-methylphenyl) -N-methylquinoline-4-carboxamide;

1-76: 3-(4-{[(2S)-2-aminopropyl](methyl)carbamoyl}-3-(3-fluoro-5-methylphenyl)quinolin-6-yl)-5-methoxybenzoic acid;

1-76: 6-[3-cyano-5-(methylcarbamoyl)phenyl]-3-(3-fluoro-5-methylphenyl)-N-methyl-N-[(2S) -pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

1-77: 6-(3-cyano-2-hydroxyphenyl)-3-(3-fluoro-5-methylphenyl)-N-methyl-N-[(2S)-pyrrolidin -2-ylmethyl]quinoline-4-carboxamide;

1-78: 6-(3-carbamoyl-5-cyanophenyl)-3-(3,5-difluorophenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

1-79: 6-(3-cyano-5-fluorophenyl)-3-(3-fluoro-5-methylphenyl)-N-{[(2S,4R)-4-fluoropyrrolidin -2-yl]methyl}-N-methylquinoline-4-carboxamide;

1-80: N-[(2S)-azetidin-2-ylmethyl]-3-(3-chloro-5-methylphenyl)-6-(3-cyano-5-fluorophenyl)-N -methylquinoline-4-carboxamide;

1-81: N-[(2S)-azetidin-2-ylmethyl]-6-(3-carbamoyl-5-fluorophenyl)-3-(3-chloro-5-methylphenyl)-N-methylquinoline-4-carboxamide;

1-82: N-[(2S)-azetidin-2-ylmethyl]-6-(3-cyano-5-fluorophenyl)-3-(3,5-dichlorophenyl)-N -methylquinoline-4-carboxamide;

1-83: N-[(2S)-azetidin-2-ylmethyl]-6-(3-carbamoyl-5-fluorophenyl)-3-(3,5-dichlorophenyl)-N -methylquinoline-4-carboxamide;

1-84: N-[(2S)-azetidin-2-ylmethyl]-3-(3-chloro-5-methylphenyl)-6-(3-cyano-2-hydroxyphenyl) -N-methylquinoline-4-carboxamide;

1-85: N-[(2S)-azetidin-2-ylmethyl]-6-(3-cyano-2-hydroxyphenyl)-3-(3,5-dichlorophenyl)-N -ethylquinoline-4-carboxamide;

1-86: N-[(2S)-azetidin-2-ylmethyl]-3-(3-chloro-5-fluorophenyl)-6-(3-cyano-2-hydroxyphenyl) -N-methylquinoline-4-carboxamide;

1-87: 3-(3-chloro-5-fluorophenyl)-6-(3-cyano-2-hydroxyphenyl)-N-methyl-N-[(2S)-pyrrolidin -2-ylmethyl]quinoline-4-carboxamide;

1-88: 6-(3-carbamoyl-5-methylphenyl)-3-(3-chloro-5-fluorophenyl)-N-methyl-N-[(2S) -pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

1-89: N-[(2S)-2-amino-4-fluorobutyl]-6-(3,5-difluorophenyl)-3-(3-fluoro-5-methylphenyl)-N -methylquinoline-4-carboxamide;

1-90: 6-(3-cyano-5-fluorophenyl)-3-(3-fluoro-5-methylphenyl)-N- {[(2S,4S)-4-fluoropyrrolidin -2-yl]methyl}-N-methylquinoline-4-carboxamide;

1-91: 6-(3-fluoro-2-hydroxyphenyl)-3-(3-fluoro-5-methylphenyl)-N-methyl-N-[(2S)-pyrrolidin -2-ylmethyl]quinoline-4-carboxamide;

2-1: 3-(3-chloro-5-methylphenyl)-6-(3-hydroxyphenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]-1,5-naphthyridine-4-carboxamide;

2-2: 3,6-bis(3-hydroxyphenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]-1,5-naphthyridine-4-carboxamide;

2-3: 3-(3-chloro-5-methylphenyl)-6-(2-fluoro-5-hydroxyphenyl)-N-methyl-N-[(2S)-pyrrolidin -2-ylmethyl]- 1,5-naphthyridine-4-carboxamide;

2-4: 3-(3-chloro-5-methylphenyl)-6-(3-cyano-5-hydroxyphenyl)-N-methyl-N-[(2S)-pyrrolidin -2-ylmethyl]- 1,5-naphthyridine-4-carboxamide;

2-5: N-[(2S)-2-aminobutyl]-6-(3-cyano-5-hydroxyphenyl)-3-(3,5-dimethylphenyl)-N-methyl -1,5-naphthyridine-4-carboxamide;

2-6: N-[(2S)-2-aminobutyl]-3-(3-chloro-5-methylphenyl)-6-(3-cyano-5-hydroxyphenyl)-N -methyl-1,5-naphthyridine-4-carboxamide;

2-7: N-[(2S)-2-aminobutyl]-6-(3-cyano-5-hydroxyphenyl)-3-(3-fluoro-5-methylphenyl)-N -methyl-1,5-naphthyridine-4-carboxamide;

2-8: 6-(3-hydroxyphenyl)-N-methyl-3-[3-(1H-pyrazol-1-yl)phenyl]-N-[(2S)-pyrrolidin-2-ylmethyl]-1,5-naphthyridine-4-carboxamide;

2-9: 3-(3,5-difluorophenyl)-6-(3-hydroxyphenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]-1,5-naphthyridine-4-carboxamide;

2-10: 6-(3-cyano-5-fluorophenyl)-3-[3-(2-hydroxyethyl)phenyl]-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]-1,5-naphthyridine-4-carboxamide;

2-11: 6-(3-cyano-5-fluorophenyl)-N-methyl-3-phenyl-N-[(2S)-pyrrolidin-2-ylmethyl]-1,5-naphthyridine-4-carboxamide;

2-12: 6-(3-cyano-5-fluorophenyl)-3-(3-methoxyphenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]-1,5-naphthyridine-4-carboxamide;

2-13: 6-(3-cyano-5-fluorophenyl)-3-(3-fluorophenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]-1,5-naphthyridine-4-carboxamide;

2-14: 6-(3-cyano-5-fluorophenyl)-3-[3-(acetamidomethyl)phenyl]-N-methyl-N-[(2S)-pyrrolidin -2-ylmethyl]-1,5-naphthyridine-4-carboxamide;

2-15: 6-(3-cyano-5-fluorophenyl)-3-(3-cyanophenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]-1,5-naphthyridine-4-carboxamide;

2-16: 6-(3-cyano-5-fluorophenyl)-3-(3,5-difluorophenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]-1,5-naphthyridine-4-carboxamide;

2-17: 6-(3-cyano-5-fluorophenyl)-3-(3-fluoro-5-methylphenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]-1,5-naphthyridine-4-carboxamide;

2-18: 6-(3-cyano-5-fluorophenyl)-3-(3-fluoro-5-methoxyphenyl)-N-methyl-N-[(2S)-pyrrolidin -2-ylmethyl]- 1,5-naphthyridine-4-carboxamide;

2-19: 6-(3-cyanophenyl)-3-(3,5-difluorophenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]-1,5-naphthyridine-4-carboxamide;

2-20: 2-{3-[6-(3-hydroxyphenyl)-4-[methyl(pyrrolidin-2-ylmethyl)carbamoyl]-1,5-naphthyridin-3-yl]phenyl}acetic acid;

2-21: methyl 2-{3-[6-(3-hydroxyphenyl)-4-{methyl[(2S)-pyrrolidin-2-ylmethyl]carbamoyl}-1,5-naphthyridin-3-yl]phenyl}acetate;

2-22: 3-{3-[6-(3-hydroxyphenyl)-4-{methyl[(2S)-pyrrolidin-2-ylmethyl]carbamoyl}-1,5-naphthyridin-3-yl]phenyl}propanoic acid;

2-23: methyl 3-{3-[6-(3-hydroxyphenyl)-4-{methyl[(2S)-pyrrolidin-2-ylmethyl]carbamoyl}-1,5-naphthyridin-3-yl]phenyl}propanoate;

2-24: 6-(3-carbamoyl-5-fluorophenyl)-3-(3-fluoro-5-methylphenyl)-N-methyl-N-[(2S) -pyrrolidin-2-ylmethyl]-1,5-naphthyridine-4-carboxamide;

3-1: 6-(3-hydroxyphenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]-1,5-naphthyridine-4-carboxamide;

3-2: 3-(3-fluoro-5-methylphenyl)-N-methyl-6-(pyrrolidin-1-yl)-N-[(2S)-pyrrolidin-2-ylmethyl]-1,5-naphthyridine-4-carboxamide;

3-3: 3-(3-fluoro-5-methylphenyl)-6-(3-hydroxypiperidin-1-yl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]-1,5-naphthyridine-4-carboxamide;

3-4: 6-(3-hydroxyphenyl)-N-methyl-3-(pyrrolidin-1-yl)-N-[(2S)-pyrrolidin-2-ylmethyl]-1,5-naphthyridine-4-carboxamide;

3-5: 6-(3-hydroxyphenyl)-N-methyl-3-(6-methylpyridin-2-yl)-N-[(2S)-pyrrolidin-2-ylmethyl]-1,5-naphthyridine-4-carboxamide;

3-6: 3-(2,6-dimethylmorpholin-4-yl)-6-(3-hydroxyphenyl)-N-methyl-N-[(2 S)-pyrrolidin-2-ylmethyl]-1,5-naphthyridine-4-carboxamide;

3-7: 6-(3-cyano-5-fluorophenyl)-N-methyl-3-(prop-1-yn-1-yl)-N-[(2S)-pyrrolidin-2-ylmethyl]-1,5-naphthyridine-4-carboxamide;

3-8: 6-(5-cyanopyridin-3-yl)-3-(3-fluoro-5-methylphenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-9: 6-(3-cyano-5-fluorophenyl)-3-(cyclopent-1-en-1-yl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]-1,5-naphthyridine-4-carboxamide;

3-10: 3-(3-fluoro-5-methylphenyl)-N-methyl-6-(1-methyl-1H-pyrazol-4-yl)-N-[(2S)-pyrrolidin -2-ylmethyl]quinoline-4-carboxamide;

3-11: 6-(3-hydroxyphenyl)-N-methyl-3-(piperidin-1-yl)-N-[(2S)-pyrroldin-2-ylmethyl]-1,5-naphthyridine-4-carboxamide;

3-12: 6-(3-hydroxyphenyl)-N-methyl-3-(morpholin-4-yl)-N-[(2S)-pyrrolidin-2-ylmethyl]-1,5-naphthyridine-4-carboxamide;

3-13: 6-(6-cyanopyridin-2-yl)-3-(3-fluoro-5-methylphenyl)-N-methyl-N-[(2 S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-14: 6-(4-cyanopyridin-2-yl)-3-(3-fluoro-5-methylphenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-15: 6-(2-amino-5-cyanopyridin-3-yl)-3-(3-fluoro-5-methylphenyl)-N-methyl-N-[(2S) -pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-16: 6-(2-cyanopyridin-4-yl)-3-(3-fluoro-5-methylphenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-17: 3-[3-(hydroxymethyl)pyrrolidin-1-yl]-6-(3-hydroxyphenyl)-N-methyl-N-[(2S)-pyrrolidin -2-ylmethyl]-1,5-naphthyridine-4-carboxamide;

3-18: 6-(3-hydroxyphenyl)-N-methyl-3-(prop-1-yn-1-yl)-N-((2S)-pyrrolidin-2-ylmethyl)-1,5-naphthyridine-4-carboxamide;

3-19: 6-(4-cyanopyrimidin-2-yl-3-(3-fluoro-5-methylphenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-20: 3-(cis-2,6-dimethylmorpholin-4-yl)-6-(3-hydroxyphenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-21: 3-(trans-2,6-dimethylmorpholin-4-yl-6-(3-hydroxyphenyl)-N-methyl-N-[(2S)-pyrrolidin -2-ylmethyl]quinoline-4-carboxamide;

3-22: 6-(5-cyano-2,4-dimethylpyridin-3-yl)-3-(3-fluoro-5-methylphenyl)-N-methyl-N-[(2S) -pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-33: 6-(2-carbamoylpyridin-4-yl)-3-(3-fluoro-5-methylphenyl)-N-methyl-N-[(2S)-pyrrolidin -2-ylmethyl]quinoline-4-carboxamide;

3-34: 6-(3-cyano-5-fluorophenyl)-3-(2-fluoro-3,5-dimethylphenyl)-N-methyl-N-[(2S) -pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-35: 6-(3-cyano-5-fluorophenyl)-3-(2,6-dimethylmorpholin-4-yl)-N-methyl-N-[(2S) -pyrrolidin-2-ylmethyl]-1,5-naphthyridine-4-carboxamide;

3-36: 6-(3-cyano-5-fluorophenyl)-3-(2,6-dimethylmorpholin-4-yl)-N-methyl-N-[(2S) -pyrrolidin-2-ylmethyl]-1,5-naphthyridine-4-carboxamide;

3-37: 6-[5-cyano-2-(methylamino)pyridin-3-yl]-3-(3-fluoro-5-methylphenyl)-N-methyl-N -[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-38: 6-[5-cyano-2-(dimethylamino)pyridin-3-yl]-3-(3-fluoro-5-methylphenyl)-N-methyl-N -[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-39: 6-(5-cyano-2-methylpyridin-3-yl)-3-(3-fluoro-5-methylphenyl)-N-methyl-N-[(2S) -pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-40: 6-(5-cyanopyridin-3-yl)-3-[3-fluoro-5-(2-hydroxyethyl)phenyl]-N-methyl-N-[(2S) -pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-41: N-[(2S)-2-aminobutyl]-6-[5-cyano-2-(dimethylamino)pyridin-3-yl]-3-(3-fluoro-5-methylphenyl)-N-methylquinoline-4-carboxamide;

3-42: 6-(3-cyano-5-fluorophenyl)-N-methyl-3-[(2R)-2-phenylmorpholin-4-yl]-N-[(2S) -pyrrolidin-2-ylmethyl]-1,5-naphthyridine-4-carboxamide;

3-43: 6-(3-cyano-5-fluorophenyl)-N-methyl-3-(3-methylbutyl)-N-[(2S)-pyrrolidin-2-ylmethyl]-1,5-naphthyridine-4-carboxamide;

3-44: 6-(6-carbamoylpyrazin-2-yl)-3-(3-fluoro-5-methylphenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-45: 6-(3-cyano-5-fluorophenyl)-3-(2,6-dimethylmorpholin-4-yl)-N-methyl-N-[(2S) -pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-46: 3-(3-fluoro-5-methylphenyl)-N-methyl-6-[6-(methylcarbamoyl)pyridin-2-yl]-N-[(2S) -pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-47: 6-(3-cyano-5-fluorophenyl)-N-methyl-3-[(2S)-2-phenylmorpholin-4-yl]-N-[(2S) -pyrrolidin-2-ylmethyl]-1,5-naphthyridine-4-carboxamide;

3-48: 3-(3-fluoro-5-methylphenyl)-N-methyl-6-(pyridin-3-yl)-N-[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-49: 6-(3-cyano-5-fluorophenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]-3-(2,2,6,6-tetramethylmorpholin-4-yl)-1,5-naphthyridine-4-carboxamide;

3-50: 6-(3-carbamoyl-4,5-difluorophenyl)-3-(3-fluoro-5-methylphenyl)-N-methyl-N-[(2S) -pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-51: 6-(6-aminopyridin-2-yl)-3-(3-fluoro-5-methylphenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-52: 6-(3-carbamoyl-2,5-difluorophenyl)-3-(3-fluoro-5-methylphenyl)-N-methyl-N-[(2S) -pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-53: 3-(3-fluoro-5-methylphenyl)-6-(6-methoxypyridin-2-yl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-54: 6-(3-cyano-5-fluorophenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]-3-[5-(trifluoromethyl)-2,3-dihydro-1H-indol-1-yl]-1,5-naphthyridine-4-carboxamide;

3-55: 6-(3-cyano-5-fluorophenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]-3-[5-(trifluoromethyl)-2,3-dihydro-1H-isoindol-2-yl]-1,5-naphthyridine-4-carboxamide;

3-56: 6-(5-cyano-2-hydroxypyridin-3-yl)-3-(3-fluoro-5-methylphenyl)-N-methyl-N-[(2S) -pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-57: 6-(6-carbamoyl-3-methylpyridin-2-yl)-3-(3-fluoro-5-methylphenyl)-N-methyl-N-[(2S) -pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-58: 6-(5-carbamoylpyridin-3-yl)-3-[3-fluoro-5-(2-hydroxyethyl)phenyl]-N-methyl-N-[(2S) -pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-59: 3-(3-fluoro-5-methylphenyl)-6-(5-fluoropyridin-3-yl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-60: 3-(3-fluoro-5-methylphenyl)-6-(1H-indo1-6-yl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-61: 3-(3-fluoro-5-methylphenyl)-6-(1H-indol-4-yl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-62: 6-(2-amino-5-fluoropyridin-3-yl)-3-(3-fluoro-5-methylphenyl)-N-methyl-N-[(2S) -pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-64: 6-(3-carbamoyl-5-fluorophenyl)-3-[(cis)-2,6-dimethylmorpholin-4-yl]-N-methyl-N-[(2S) -pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-65: 3-(3-fluoro-5-methylphenyl)-N-methyl-6-(4-methylpyridin-3-yl)-N-[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-66: 3-(3-fluoro-5-methylphenyl)-N-methyl-6-(1-oxo-2,3-dihydro-1H-isoindol-4-yl)-N-[(2S) -pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-67: N-[(2S)-2-aminobutyl]-6-(6-carbamoylpyridin-2-yl)-3-(3-fluoro-5-methylphenyl)-N -methylquinoline-4-carboxamide;

3-68: 6-(5-chloropyridin-3-yl)-3-(3-fluoro-5-methylphenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-69: 3-{3-azabicyclo[3.1.0]hexan-3-yl}-6-(3-cyano-5-fluorophenyl)-N-methyl-N-[(2S) -pyrrolidin-2-ylmethyl]-1,5-naphthyridine-4-carboxamide;

3-70: 6-(3-cyano-5-fluorophenyl)-N-methyl-3-{8-oxa-3-azabicyclo[3.2.1]octan-3-yl}-N-[(2S) -pyrrolidin-2-ylmethyl]-1,5-naphthyridine-4-carboxamide;

3-71: 3-(3-fluoro-5-methylphenyl)-N-methyl-6-(pyrimidin-5-yl)-N-[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-72: 6-[4-cyano-6-(morpholin-4-yl)pyridin-2-yl]-3-(3-fluoro-5-methylphenyl)-N-methyl-N -[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-73: 3-(3-fluoro-5-methylphenyl)-N-methyl-6-[2-oxo-6-(trifluoromethyl)-2,3-dihydro-1H -1,3-benzodiazol-4-yl]-N-[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-74: 3-(3-fluoro-5-methylphenyl)-6-(4-fluoropyridin-3-yl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-75: 6-(4-chloropyridin-3-yl)-3-(3-fluoro-5-methylphenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-76: 6-(3-cyano-5-fluorophenyl)-3-(3,3-difluoropyrrolidin-1-yl)-N-methyl-N-[(2S)-pyrrolidin -2-ylmethyl]-1,5-naphthyridine-4-carboxamide;

3-77: 6-(6-carbamoylpyridin-2-yl)-3-(3,5-difluorophenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-78: 6-(6-carbamoyl-3-fluoropyridin-2-yl)-3-(3-fluoro-5-methylphenyl)-N-methyl-N-[(2S) -pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-79: 6-(6-carbamoyl-3-methylpyridin-2-yl)-3-(3,5-difluorophenyl)-N-methyl-N-[(2S) -pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-80: 6-(4-carbamoylpyridin-2-yl)-3-(3-fluoro-5-methylphenyl)-N-methyl-N-[(2S)-pyrrolidin -2-ylmethyl]quinoline-4-carboxamide;

3-81: 3-(3-fluoro-5-methylphenyl)-6-(5-methoxypyridin-3-yl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-82: 3-(3-fluoro-5-methylphenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]-6-(6-sulfamoylpyridin-2-yl)quinoline-4-carboxamide;

3-83: 3-(3-fluoro-5-methylphenyl)-N-methyl-6-(5-methylpyridin-3-yl)-N-[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-84: 3-(3-fluoro-5-methylphenyl)-6-[5-(hydroxymethyl)pyridin-3-yl]-N-methyl-N-[(2S) -pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-85: 3-(3-chloro-5-methylphenyl)-6-(5-hydroxypyridin-3-yl)-N,7-dimethyl-N-[(2S)-pyrrolidin -2-ylmethyl]-3,4-dihydroquinazoline-4-carboxamide;

3-86: 6-[5-(difluoromethoxy)pyridin-3-yl]-3-(3-fluoro-5-methylphenyl)-N-methyl-N-[(2S) -pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-87: ethyl (2S)-2({1-[6-(6-carbamoylpyridin-2-yl)-3-(3-fluoro-5-methylphenyl)quinolin-4-yl]-N-methylformamido}methyl)pyrrolidine-1-carboxylate;

3-88: 6-(6-carbamoylpyridin-2-yl)-3-(3-chloro-5-methylphenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-89: 6-(6-carbamoyl-3-fluoropyridin-2-yl)-3-(3-chloro-5-methylphenyl)-N-methyl-N-[(2S) -pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-90: 6-(6-carbamoyl-3-methylpyridin-2-yl)-3-(3-chloro-5-methylphenyl)-N-methyl-N-[(2S) -pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-91: 6-(6-carbamoyl-3-chloropyridin-2-yl)-3-(3-chloro-5-methylphenyl)-N-methyl-N-[(2S) -pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-92: N-[(2S)-azetidin-2-ylmethyl]-6-(6-carbamoylpyridin-2-yl)-3-(3-fluoro-5-methylphenyl) -N-methylquinoline-4-carboxamide;

3-93: N-[(2S)-azetidin-2-ylmethyl]-6-(6-carbamoyl-3-fluoropyridin-2-yl)-3-(3-fluoro-5-methylphenyl)-N-methylquinoline-4-carboxamide;

3-94: N-[(2S)-azetidin-2-ylmethyl]-6-(6-carbamoyl-3-methylpyridin-2-yl)-3-(3-fluoro-5-methylphenyl)-N-methylquinoline-4-carboxamide;

3-95: N-[(2S)-azetidin-2-ylmethyl]-6-(6-carbamoyl-3-chloropyridin-2-yl)-3-(3-fluoro-5-methylphenyl)-N-methylquinoline-4-carboxamide;

3-96: 6-(6-carbamoylpyridin-2-yl)-3-(3,5-dichlorophenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-97: 6-(6-carbamoyl-3-fluoropyridin-2-yl)-3-(3,5-dichlorophenyl)-N-methyl-N-[(2S) -pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-98: 6-(6-carbamoyl-3-methylpyridin-2-yl)-3-(3,5-dichlorophenyl)-N-methyl-N-[(2S) -pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-99: 6-(6-carbamoyl-3-chloropyridin-2-yl)-3-(3,5-dichlorophenyl)-N-methyl-N-[(2S) -pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-100: N-[(2S)-azetidin-2-ylmethyl]-6-(6-carbamoylpyridin-2-yl)-3-(3,5-dichlorophenyl)-N -methylquinoline-4-carboxamide;

3-101: N-[(2S)-azetidin-2-ylmethyl]-6-(6-carbamoyl-3-fluoropyridin-2-yl)-3-(3,5-dichlorophenyl)-N-methylquinoline-4-carboxamide;

3-102: N-[(2S)-azetidin-2-ylmethyl]-6-(6-carbamoyl-3-methylpyridin-2-yl)-3-(3,5-dichlorophenyl)-N-methylquinoline-4-carboxamide;

3-103: N-[(2S)-azetidin-2-ylmethyl]-6-(6-carbamoyl-3-chloropyridin-2-yl)-3-(3,5-dichlorophenyl)-N-methylquinoline-4-carboxamide;

3-104: 6-(6-carbamoylpyridin-2-yl)-3-(3-fluoro-5-methylphenyl)-N-methyl-N-{[(2S)-1-methylpyrrolidin-2-yl]methyl}quinoline-4-carboxamide;

3-105: 3-(3-fluoro-5-methylphenyl)-N-methyl-N-[(2S)-pyrrolidin-2-ylmethyl]-6-[5-(trifluoromethyl)pyridin-3-yl]quinoline-4-carboxamide;

3-106: 3-(3-fluoro-5-methylphenyl)-N-methyl-6-(4-oxo-3,4-dihydro-2H-1,3-benzoxazin-6-yl) -N-[(2S)-pyrrolidin-2-ylmethyl]quinoline-4-carboxamide;

3-107: 6-(3,5-difluoro-2-hydroxyphenyl)-3-(3-fluoro-5-methylphenyl)-N-methyl-N-[(2S) -pyrrolidin-2-ylmethyl]quinoline-4-carboxamide.

or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, diastereomeric mixture, or individual enantiomers thereof.

18. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt, solvate, diastereomeric mixture, or individual enantiomers thereof, and at least one pharmaceutically acceptable excipient.

19. A method of treating a disease or condition in a mammal that would benefit from the modulation of the somatostatin receptor subtype 2 (SSTR2) activity comprising administering a compound of claim 1 , or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, diastereomeric mixture, or individual enantiomers thereof, to the mammal in need thereof; wherein the disease or condition is acromegaly, a neuroendocrine tumor, or combinations thereof.